Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities

Journal of Clinical Oncology

Volumn 15, Issue 12, 1997, Pages 3464-3470

  Hainsworth, John D ^a   Gray, James R ^a   Stroup, Steven L ^a   Kalman, Leonard A ^a   Patten, Judd E ^a   Hopkins, Lisa G ^a   Thomas, Melodie ^a   Greco, F A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; CYTOKINE; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030686594     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.12.3464     Document Type: Article

References (27)

1. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12:2022-2034, 1996
2. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993
3. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
4. Kirschling RJ, Jung SH, Jett JR: A phase II trial of Taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13:326, 1994 (abstr)
5. Hainsworth JD, Greco FA: Paclitaxel administered by one-hour infusion: Preliminary results of a phase I/II trial comparing two schedules. Cancer 74:1377-1382, 1994
6. Hainsworth JD, Raetsky EL, Thomas M, et al: Paclitaxel administered by 1-hour infusion: Phase I/II study comparing two schedules of administration. Cancer J Sci Am 1:281-287, 1995
7. Hainsworth JD, Stroup SL, Greco FA: Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer 77:2458-2463, 1996
8. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by one-hour infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 13:1609-1614, 1995
9. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response and survival analysis. J Clin Oncol 13:1860-1870, 1995
10. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
11. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973 (letter)
12. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
14. Loehrer PJ, Ansari R, Ganin R, et al: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol 13:2594-2599, 1995
15. Evans WK, Sheperd FA, Feld R, et al: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471-1477, 1985
16. Kasmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/ etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study. Semin Oncol 21:23-30, 1994 (suppl 3)
17. Boni C, Cocconi G, Bisagni G, et al: Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer: A phase II trial. Cancer 63:638-642, 1989
18. Jeremic B, Shibamoto Y, Acimoric L, et al: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 15:893-900, 1997
19. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: A multicenter, randomized trial by the National Cancer Institute of Canada. Ann Intern Med 107:451-458, 1987
20. Livingston RB, Crowley JJ, Thompson T, et al: Prolonged alternating chemotherapy for extensive small cell lung cancer: A Southwest Oncology Group study. Cancer 71:3509-3513, 1993
21. Wolff AC, Ettinger DS, Neuberg D, et al: Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 13:1615-1622, 1995
22. Katakami N, Takada M, Negoro S, et al: Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the Lung Cancer Study Group of West Japan. Cancer 77:63-70, 1996
23. Postmus PE, Scagliotti G, Groen HJM, et al: Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC phase III trial. Eur J Cancer 32A:1498-1503, 1996
24. Sculier JP, Paesmans M, Burean G, et al: Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell lung cancer. J Clin Oncol 14:2337-2344, 1996
25. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 5:283-285, 1994
26. Perez-Soler R, Glisson BS, Lee JS, et al: Phase II study of topotecan in patients with small cell lung cancer refractory to etoposide. Proc Am Soc Clin Oncol 14:355, 1995 (abstr)
27. Masuda N, Fukuoka M, Kusunaki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992